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Substantial amounts of data have been generated from patient management and academic exercises designed to better
understand the human immunodeficiency virus (HIV) epidemic and design interventions to control it. A number of
specialized databases have been designed to manage huge data sets from HIV cohort, vaccine, host genomic and
drug resistance studies. Besides databases from cohort studies, most of the online databases contain limited curated
data and are thus sequence repositories. HIV drug resistance has been shown to have a great potential to derail the
progress made thus far through antiretroviral therapy. Thus, a lot of resources have been invested in generating drug
resistance data for patient management and surveillance purposes. Unfortunately, most of the data currently available
relate to subtype B even though >60% of the epidemic is caused by HIV-1 subtype C. A consortium of clinicians,
scientists, public health experts and policy markers working in southern Africa came together and formed a network,
the Southern African Treatment and Resistance Network (SATuRN), with the aim of increasing curated HIV-1 subtype C
and tuberculosis drug resistance data. This article describes the HIV-1 data curation process using the SATuRN Rega
database. The data curation is a manual and time-consuming process done by clinical, laboratory and data curation
specialists. Access to the highly curated data sets is through applications that are reviewed by the SATuRN executive
committee. Examples of research outputs from the analysis of the curated data include trends in the level of transmitted
drug resistance in South Africa, analysis of the levels of acquired resistance among patients failing therapy and
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factors associated with the absence of genotypic evidence of drug resistance among patients failing therapy. All these
studies have been important for informing first- and second-line therapy. This database is a free password-protected
open source database available on www.bioafrica.net.
Database URL: http://www.bioafrica.net/regadb/
.............................................................................................................................................................................................................................................................................................
Introduction
The international response to the human immunodefi-
ciency virus (HIV) pandemic has been characterized by un-
precedented speed and depth that was only possible
through collaboration of clinicians, scientists and civil soci-
ety including many disciplines and research groups. As a
result of this process, the study of the HIV epidemic has
generated substantial amount of data. In addition, because
HIV is one of the first organisms for which genomic data
have been used to identify resistance to drugs and to trace
its origin, hundreds of thousands of subgenomic regions
have been sequenced both from the management of pa-
tients infected by the virus and from academic endeavors to
try to understand the epidemic and to discover and develop
interventions.
Numerous public databases, such as the Los Alamos HIV
Database and the Stanford HIV Drug Resistance Database,
have been created to manage the burgeoning number of
HIV genomic data sets (1, 2). These databases provide plat-
forms for academics to share and compare data as well as
to answer new research questions not originally envisioned
by the original investigators. However, a limitation of these
public databases is that they do not store and curate data
before publication. Moreover, these databases are primar-
ily sequence repositories and contain limited clinical data.
Therefore, there is a need for databases to manipulate and
curate primary data that include both sequence data and
associated clinical, treatment and monitoring data.
In this article, we describe the online database of the
Southern African Treatment and Resistance Network
(SATuRN). The network is a consortium of clinicians, scien-
tists, public health experts and policy makers (3). The net-
work has 24 member institutions working in southern
Africa at the epicenter of the HIV and tuberculosis (TB) epi-
demics. To foster collaboration among members and to
curate primary data, the SATuRN RegaDB HIV Drug
Resistance and Clinical Management Database (http://
www.bioafrica.net/regadb/index.html) was established.
RegaDB is an integrated open source relational database
for the management and analysis of HIV treatment, moni-
toring and resistance data (4). The database is designed
to facilitate individual patient management and also to
enable real-time surveillance and research, ultimately to
inform public health policies in the region.
SATuRN member sites are encouraged to use RegaDB for
real-time management of patients failing antiretroviral
therapy (ART). It is configured to incorporate a number of
online analytic tools such as the Rega HIV Subtyping tool (5)
and drug resistance interpretation tools such as HIVDB (6),
REGA (7) and ANRS (8, 9). The database is used to produce
genotypic resistance reports with specialist advice on thera-
peutic options tailored to the clinical and treatment history
data provided by the clinicians. As a consequence, medical
officers and nurses are impelled to provide detailed data to
receive robust advice, and this cycle drives quality data
curation.
In this article, we first describe the data collection meth-
ods followed by a description of the data curation process.
We also provide information on database users, data shar-
ing and access policy. We conclude the article with
examples of how our curated data have been used for bio-
logical discovery.
Data collection and curation
process: primary data
A clinical case report form was developed for the collection
of demographic and clinical information, treatment data
and laboratory monitoring data for input into the
SATuRN RegaDB (Supplementary Information). All data
are anonymized at the point of entry to the database,
but secure records held separately allow linkage to patient
care and access to follow-up data. The medical officers or
nurses managing the patient send the completed form to-
gether with a blood sample submitted for genotypic resist-
ance testing to a central laboratory. The sample is used to
produce an HIV-1 DNA sequence of the protease (PR) and
reverse transcriptase (RT) genes, which are HIV-1 proteins
targeted by first- and second-line ART regimens in southern
Africa. Genotypic resistance testing is performed using the
in-house SATuRN/Life Technologies method (10). The geno-
type is translated, and drug resistance mutations are char-
acterized with the use of the drug resistance algorithms
contained within RegaDB.
The demographic data collected includes age and sex.
Patient identifiers such as names and national identity
(ID) numbers are not stored in the RegaDB database. All
the stored data are anonymized, and it is the responsibility
of the medical officers to link the data to the patient for
clinical management. Laboratory data include the patient’s
viral load and CD4+ cell count results; in addition, hepatitis
B virus surface antigen (HBsAg), creatinine clearance,
.............................................................................................................................................................................................................................................................................................
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hemoglobin and alanine aminotransferase results, pertin-
ent to future treatment decisions, are also included.
The treatment information focuses on the ART history as
well as treatments for comorbid conditions, in particular TB
and hepatitis B virus, as these influence the selection of ART
regimens. The start and end dates of specific ART regimens
are recorded, with dosages and reasons for any substitution
or switch of ART. The clinical form also includes a series of
questions relating to adherence, which are based on the
assessment tools within the South African national guide-
lines, and social factors that may influence adherence such
as alcohol intake.
Once the HIV genomic data are generated and up-
loaded, they pass through a quality control step, which in-
cludes analysis for deletions, insertions and frame shifts, as
well as for contamination using the Basic Local Alignment
Search Tool (BLAST) (11) and phylogenetic methods. The
genomic sequence is also subtyped using phylogenetic
methods that can identify recombinants (5). The PR and
RT proteins are analyzed by a pre-selected drug resistance
algorithm, such as Stanford HIVDB or REGA algorithm or
ANRS, to identify drug resistance mutations and provide an
assessment of the level of resistance. The drug resistance
interpretation, together with a graphical history of the pa-
tient’s ART and laboratory monitoring history, is presented
in the form of a report in MS Word (.doc) and rich text
format (.rtf) (Figure 1).
All SATuRN member institutions are encouraged to use
SATuRN’s RegaDB database reports for the management of
patients failing ART. Specialist clinician advice in the report
adheres, wherever possible, to regimens included within
national treatment guidelines. Non-standard regimens are
only recommended when there is a strong justification, and
any request for ARTs outside the national guidelines re-
quires further approval by the Department of Health. The
public health approach to ART is of crucial importance to
southern Africa, as >4 million patients are on treatment in
the region and the great majority of patients receive treat-
ment at primary health care clinics, with limited pharma-
ceutical and medical support.
The data are reviewed at many stages to seek out incon-
sistency and improve quality. Figure 2 shows a model ex-
ample of the data sources and the review and curation
steps. In this model, data from the clinical case report
form are added to the database by a team of data curators.
Two independent data clerks are involved in the data entry
process—one enters the data and the other reviews the
data to ensure accurate data entry. In addition, the clinical
form is sent to the laboratory staff and the specialist clin-
icians. The laboratory staff are trained to interpret the
clinical chart and to ensure that it makes biological sense
(for example, a suppressed viral load result is not usually
plausible unless the patient was on treatment at the time).
The specialist clinicians ensure that the resistance levels are
Figure 1. SATuRN Resistance report example. The first page of
the report provides a table with drug resistance mutation. The
second page contains clinical chart and written interpretation
of clinical chart and resistance and a specialized infectious
diseases (I.D.) physician switch interpretation.
.............................................................................................................................................................................................................................................................................................
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consistent with the drug regimens received by the patient,
and write a detailed therapy recommendation (Figure 1)
that is added to the database.
The whole process described in Figure 2 takes, on aver-
age, 10–14 days. This process is part of the HIV Treatment
Failure Clinic (HIV-TFC) model (12). It is important that the
data curation is expedited as the patient follow-up visit is
normally scheduled for 3–4 weeks after the initial visit at
which the blood sample was taken. To receive a detailed
report including specialist clinicians comments, the medical
officers managing the patients need to complete the clin-
ical form accurately. This motivates them to supply accurate
information. Although the processes of data cleaning, val-
idation and curation described here might seem laborious
and time-consuming, the quality data obtained from this
process are worth the investment. This is especially true in
the context of reports of significant weaknesses of the gen-
eral public health program data in the region (13, 14).
Furthermore, the use of a specialized physician to interpret
drug resistance results is the norm in South Africa and
Botswana public health HIV treatment programs (15).
However, a process evaluation has been performed to
review the whole system and identify areas that still need
further optimization so as to deliver the most cost-efficient
system while maintaining quality.
Data collection and curation:
published data
Published manuscripts on PubMed with linked sequence
data deposited in Genbank, but not yet in the REGA data-
base, are identified on a regular basis to add to the data-
base. The search terms used are ‘HIV-1’, ‘drug resistance’
and ‘Africa’. Only studies with data from patients from
southern Africa are included. The manuscripts are reviewed
to extract treatment and monitoring data linked to the se-
quences. If there are limited data, the authors are con-
tacted directly with a request for further information
related to the sequences. All published HIV-1 genomic se-
quences pass through a quality analysis process. These in-
clude translation of all sequences and identification of
deletions, insertions and frame shifts. Sequences with
more than three stop codons, frame shifts, deletions or
highly ambiguous nucleotides are flagged and the authors
contacted to ensure that these sequence problems are real.
Sequences are also checked for duplicates in the RegaDB
database with the usage of BLAST and phylogenetic meth-
ods. Sequences with high similarity to other sequences in
RegaDB (i.e. 98%) using a clustering method with boot-
strap support (>70%) with another sequence in the phyl-
ogeny are flagged as potential duplicates and authors
contacted to determine whether these sequences arise
from samples from the same individual or whether this is
a sequence already deposited at the SATuRN RegaDB.
Database users and data access
policies
Currently there are six large cohorts using the SATuRN
REGA database for clinical management of patients failing
ART (The ANRS 12249 Treatment as Prevention trial in rural
KwaZulu-Natal hosted by the Africa Centre for Health and
Population Studies, The Hlabisa HIV Treatment and Care
Programme in partnership with the Africa Centre for
Health and Population Studies, University of Pretoria
Medical School, University of Stellenbosch Medical School,
University of the Free State Medical School, Inkosi Albert
Luthuli Central Hospital, Durban). In addition, another
eight groups have published data that have been curated
in the REGA database (Table 1). In total, 7000 genotypes
with related treatment and monitoring data have been
collated to date. The data sets increase at a rate of >200
genotypes a month, so the database is continually expand-
ing. Each genotype in the database belongs to a single
data set. Genotypes are associated with the previously
described attributes (clinical, adherence and demographic
Figure 2. An example of the stages of data curation to in-
crease the quality of the data in the SATuRN RegaDB. The
primary data source includes the patient’s clinical information
(e.g. viral load, CD4+ count and treatment regimens) that is
stored in the patient file, access to National Department of
Health ART program database that contains similar clinical
information as the patient’s clinical information and the gen-
eration of a viral genomic isolate for the pol gene. These data
are reviewed by a data curator and added to the database
by a data enterer. A report is produced, which is further
reviewed by at least one laboratory staff member, a clinical
specialist and a physician managing the patient at the
primary health care clinic. Any inconsistency on the data is
discussed between the individuals reviewing the data and
data curator.
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information), laboratory measurements (CD4+ cell count,
viral load) and ART regimens (start and stop dates) and
viral genotypes. Each data set has a unique identifier,
access is password-controlled and the owner of the data
set has the authority to allocate access to collaborators at
different levels (read only, or read and write).
SATuRN collaborators and external researchers can pro-
pose and develop scientific projects and analyses that ad-
dress new scientific hypotheses. To access comprehensive
longitudinal data stored in SATuRN, RegaDB researchers
have to submit a project proposal to the SATuRN
Executive Committee, which is composed of the SATuRN
co-directors, two clinicians and two basic scientist. The
project leader must declare his/her intention to develop a
project and also declare the main objectives. The project
leader should also provide a detailed timeline (e.g. project
initiation, data collection and the production of reports,
abstracts and manuscripts) and a list of resources available
and/or required. A concept sheet is used for the initial sub-
mission procedure. The concept sheet and process are
described in detail on the SATuRN Web site (http://www.
bioafrica.net/saturn).
SATuRN RegaDB genotypes are deposited in GenBank
after publication. The data deposited in GenBank are lim-
ited to basic demographic information (age and sex), coun-
try of origin and isolation year. Genomic data are also
deposited in the Stanford HIVDB, complemented with a
list of antiretroviral drugs received before the genotype.
Furthermore, RegaDB has an automatic export function
that is compatible with GenBank and Stanford HIVDB.
This is an important process for SATuRN, as one of its
aims is to increase the amount of public genotypic drug
resistance data in Africa. As part of this process, we have
also installed and made publicly available the first mirror of
the Stanford HIVDB in Africa (3).
Example of biological discoveries
A literature review and data analysis was performed to
review the temporal trends of HIV-1 transmitted drug re-
sistance (TDR) in South Africa (16). Publicly available data
were retrieved either from GenBank or by direct request to
original authors. Ten data sets with 1618 sequences col-
lected between 2000 and 2010 were pooled, with 72 se-
quences from recent sero-converters from the Africa
Centre’s (AC) 2010 HIV survey in KwaZulu-Natal, South
Africa. All of the data were curated and stored in SATuRN
RegaDB and were analyzed using the Calibrated Population
Resistance Program (17). There was no evidence of TDR
from the AC samples.The temporal analysis for South
Africa showed that 2002 was the year with the highest
TDR rate (6.67, 95% confidence interval: 3.09–13.79%).
After 2002, TDR levels decreased to <5% (WHO low-level
TDR threshold). There was no statistically significant
increase in the interval between 2002 and 2010. These re-
sults were published and discussed with the National
Department of Health, as they conflicted with a recent pub-
lication(18) that pointed to an increase in TDR in KwaZulu-
Natal. A large collaborative national survey involving
SATuRN investigators and the National Department of
Health is currently in process. Continuous representative
TDR surveys are needed to ensure that current first-line
regimens remain effective, as an increase in TDR could re-
verse the gains of ARV rollout.
Results from an analysis of data on SATuRN RegaDB for
patients with first-line antiretroviral treatment failure in a
rural primary health care program in KwaZulu-Natal were
recently published (19). A secondary analysis to identify fac-
tors associated with the absence of HIV drug resistance in
patients with failure of first-line ART to inform adherence
strategies and to determine whether unnecessary switches
to second-line therapy could be avoided was also done (20).
In total, 243 patients were included in the final analysis,
and detailed adherence and clinical information was
curated from clinics in the Hlabisa Treatment and Care
Programme, South Africa (Appendix). The genotypes were
linked to 38 other adherence and clinical variables. This in-
formation was reviewed by two data clerks and a medical
officer and added to RegaDB. Predictors associated with
the absence of drug resistance were analyzed by univari-
able and multivariable logistic regression methods. These
data curation and analysis showed that there are a
number of factors associated with the absence of drug re-
sistance following ART failure, one of which (baseline CD4+
count) is a strong association with poor adherence, which
can lead to significantly higher levels of immunological fail-
ure, putting these patients at increased risk of mortality.
The data stored in SATuRN RegaDB are currently being
used in many research projects. This article also serves to
provide details of existence of these longitudinal data sets
that are available for applications from researchers to ana-
lyze the data, as described in the SATuRN Manual of
Operation. In addition, the HIV drug resistance data
curated in the SATuRN RegaDB have provided the informa-
tion and tools to enable the education and training of
health care workers and patients. At the time of writing
this publication, clinical cases from the database have
been presented to 2050 medical officers and nurses
throughout Africa at the annual SATuRN conferences and
workshops. Moreover, 15 cases stored within RegaDB,
which highlight some of the major challenges involved in
managing patients failing ART in the public sector in south-
ern Africa, were collated and published recently as an open
access book (21), of which 10000 copies were freely dis-
tributed by SATuRN, Keth’impilo, Medicine San Fronteirs
(MSF) and the Southern African HIV Clinicians Society to
their medical officer members.
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Conclusion
The SATuRN RegaDB presented in this article is a useful tool
for patient management, data curation and capacity build-
ing. The combination of curated HIV sequence, clinical and
demographic data in this database has been used to iden-
tify important factors that are associated with drug resist-
ance in ART-naı¨ve and ART-experienced patients in
southern Africa. The SATuRN RegaDB has the potential to
become a useful resource for the regional and international
research community, similar to the United Kingdom (22)
and Swiss National Drug Resistance Databases (23, 24).
The data and database will be used to inform local and
national policy makers on the level of HIV-1 drug resistance
in southern Africa. Furthermore, guidelines of the Southern
African HIV Clinicians Society (25) have suggested that the
SATuRN drug resistance databases be used as a national
model for the management of patients failing ART. The
South African National Department of Health and the
Botswana Ministry of Health are in the process of piloting
the HIV-TFC system. In addition, efforts are currently being
made to have more contributions from other southern
African researchers as well as to reach out to other coun-
tries in sub-Saharan Africa as a whole.
Supplementary Data
Supplementary data are available at Database Online.
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